Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Childhood Medulloblastoma Revisited.

Cassia GSE, Alves CAPF, Taranath A, López NS, Oztekin O, Gonçalves FG, Patay Z.

Top Magn Reson Imaging. 2018 Dec;27(6):479-502. doi: 10.1097/RMR.0000000000000184.

PMID:
30516696
2.

[Medulloblastoma. Pathology].

Siegfried A, Delisle MB.

Neurochirurgie. 2018 Apr 24. pii: S0028-3770(18)30012-2. doi: 10.1016/j.neuchi.2017.12.006. [Epub ahead of print] French.

PMID:
29703584
3.

Childhood medulloblastoma: the paradigm shift in molecular stratification and treatment profile.

Sadighi Z, Vats T, Khatua S.

J Child Neurol. 2012 Oct;27(10):1302-7. Epub 2012 Jul 22. Review.

PMID:
22826514
4.

[Identification of a Family with SUFU Germline Deletion Based on a Case of Desmoplastic Medulloblastoma in an Infant].

Šoukalová J, Vejmělková K, Cermanová T, Kašíková K, Mikulášová A, Janyšková H, Melichárková K, Pavelka Z, Ježová M, Pospíšilová Š, Kuglík P, Valášková I, Gaillyová R, Štěrba J, Zitterbart K.

Klin Onkol. 2016;29 Suppl 1:S83-8. Czech.

PMID:
26691947
5.

Imaging Biomarkers for Adult Medulloblastomas: Genetic Entities May Be Identified by Their MR Imaging Radiophenotype.

Keil VC, Warmuth-Metz M, Reh C, Enkirch SJ, Reinert C, Beier D, Jones DTW, Pietsch T, Schild HH, Hattingen E, Hau P.

AJNR Am J Neuroradiol. 2017 Oct;38(10):1892-1898. doi: 10.3174/ajnr.A5313. Epub 2017 Aug 10.

6.

Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.

Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, Kenney AM, Brat DJ, Perry A, Yong WH, Taylor RE, Bailey S, Clifford SC, Gilbertson RJ.

Acta Neuropathol. 2011 Mar;121(3):381-96. doi: 10.1007/s00401-011-0800-8. Epub 2011 Jan 26.

7.

FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.

Remke M, Hielscher T, Korshunov A, Northcott PA, Bender S, Kool M, Westermann F, Benner A, Cin H, Ryzhova M, Sturm D, Witt H, Haag D, Toedt G, Wittmann A, Schöttler A, von Bueren AO, von Deimling A, Rutkowski S, Scheurlen W, Kulozik AE, Taylor MD, Lichter P, Pfister SM.

J Clin Oncol. 2011 Oct 10;29(29):3852-61. doi: 10.1200/JCO.2011.36.2798. Epub 2011 Sep 12.

PMID:
21911727
8.

Rapid diagnosis of medulloblastoma molecular subgroups.

Schwalbe EC, Lindsey JC, Straughton D, Hogg TL, Cole M, Megahed H, Ryan SL, Lusher ME, Taylor MD, Gilbertson RJ, Ellison DW, Bailey S, Clifford SC.

Clin Cancer Res. 2011 Apr 1;17(7):1883-94. doi: 10.1158/1078-0432.CCR-10-2210. Epub 2011 Feb 16.

9.
10.

Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.

Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford SC, Doz F, Kool M, Dufour C, Vassal G, Milde T, Witt O, von Hoff K, Pietsch T, Northcott PA, Gajjar A, Robinson GW, Padovani L, André N, Massimino M, Pizer B, Packer R, Rutkowski S, Pfister SM, Taylor MD, Pomeroy SL.

Acta Neuropathol. 2016 Jun;131(6):821-31. doi: 10.1007/s00401-016-1569-6. Epub 2016 Apr 4. Review.

11.

Adult hemispheric cerebellar medulloblastoma.

de Oliveira F, Landeiro JA, de Castro I.

Surg Neurol Int. 2018 Feb 14;9:34. doi: 10.4103/sni.sni_341_17. eCollection 2018.

12.

The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision.

Komori T.

Neurol Med Chir (Tokyo). 2017 Jul 15;57(7):301-311. doi: 10.2176/nmc.ra.2017-0010. Epub 2017 Jun 8. Review.

13.

Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis.

Łastowska M, Trubicka J, Niemira M, Paczkowska-Abdulsalam M, Karkucińska-Więckowska A, Kaleta M, Drogosiewicz M, Perek-Polnik M, Krętowski A, Cukrowska B, Grajkowska W, Dembowska-Bagińska B, Matyja E.

J Neurooncol. 2018 Jun;138(2):231-240. doi: 10.1007/s11060-018-2797-5. Epub 2018 Feb 9.

14.

Nodule formation and desmoplasia in medulloblastomas-defining the nodular/desmoplastic variant and its biological behavior.

McManamy CS, Pears J, Weston CL, Hanzely Z, Ironside JW, Taylor RE, Grundy RG, Clifford SC, Ellison DW; Clinical Brain Tumour Group.

Brain Pathol. 2007 Apr;17(2):151-64.

PMID:
17388946
15.

Molecular diagnostics in embryonal brain tumors.

Eberhart CG.

Brain Pathol. 2011 Jan;21(1):96-104. doi: 10.1111/j.1750-3639.2010.00455.x. Review.

16.

p53 Function Is Compromised by Inhibitor 2 of Phosphatase 2A in Sonic Hedgehog Medulloblastoma.

Wei Y, Maximov V, Morrissy SA, Taylor MD, Pallas DC, Kenney AM.

Mol Cancer Res. 2019 Jan;17(1):186-198. doi: 10.1158/1541-7786.MCR-18-0485. Epub 2018 Sep 17.

PMID:
30224541
17.

Sonic hedgehog-associated medulloblastoma arising from the cochlear nuclei of the brainstem.

Grammel D, Warmuth-Metz M, von Bueren AO, Kool M, Pietsch T, Kretzschmar HA, Rowitch DH, Rutkowski S, Pfister SM, Schüller U.

Acta Neuropathol. 2012 Apr;123(4):601-14. doi: 10.1007/s00401-012-0961-0. Epub 2012 Feb 21.

PMID:
22349907
18.

SHH inhibitors for the treatment of medulloblastoma.

Samkari A, White J, Packer R.

Expert Rev Neurother. 2015;15(7):763-70. doi: 10.1586/14737175.2015.1052796. Epub 2015 May 31. Review.

PMID:
26027634
19.

Medulloblastoma, WNT-activated/SHH-activated: clinical impact of molecular analysis and histogenetic evaluation.

Cambruzzi E.

Childs Nerv Syst. 2018 May;34(5):809-815. doi: 10.1007/s00381-018-3765-2. Epub 2018 Mar 26. Review.

PMID:
29582169
20.

Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.

Schwalbe EC, Lindsey JC, Nakjang S, Crosier S, Smith AJ, Hicks D, Rafiee G, Hill RM, Iliasova A, Stone T, Pizer B, Michalski A, Joshi A, Wharton SB, Jacques TS, Bailey S, Williamson D, Clifford SC.

Lancet Oncol. 2017 Jul;18(7):958-971. doi: 10.1016/S1470-2045(17)30243-7. Epub 2017 May 22.

Supplemental Content

Support Center